Injective trades at $14.21, holding the $12.20 support level that has historically triggered bullish reversals.
A breakout and close above $15.39 could trigger a rally toward the $20 resistance zone.
Failure to hold $12.20 risks a retracement toward the $10.00–$9.50 accumulation area.
Injective (INJ) is maintaining a trend above its support line of $12.20, and the present price actions display the probability of a surge to the price range top of $15.39 and a rally to the price level of 20.00 should the resistance point be recuperated.
Price Holds Key Support at $12.20
Injective is trading at $14.21 as of the time of writing, registering a 9.06% gain in the last 24 hours and 9.83% over the past week. The price is firmly holding the $12.20 support level, which has historically provided a launchpad for bullish reversals.
According to a recent update from Lennaert Snyder (@LennaertSnyder), $INJ is “perfectly respecting the levels,” with price action aligning closely with pre-identified zones. Maintaining this support keeps the asset positioned for a possible surge toward the next resistance at $15.39.
Breakout Above $15.39 Could Trigger Rally
The $15.39 level represents the range high that has repeatedly capped upward momentum since June. A successful reclaim and sustained close above this threshold would signal a renewed bullish trend and could lead to a swift move toward $20.00.
This upper target is marked as a major technical objective on Snyder’s chart. If reached, it would place INJ firmly in breakout territory, potentially attracting increased speculative and institutional interest.
Downside Risks Remain in Play
Failure to maintain the $12.20 support could expose the price to a deeper correction toward the $10.00–$9.50 range. This lower green zone has acted as a prior accumulation base, aligning with historical market structures.
Momentum recovery will depend on strong volume during resistance reclaims and broader market alignment. If buying pressure intensifies, Injective could see one of its most decisive rallies in recent months.
